A multicenter evaluation of a new EUS core biopsy needle: Experience in 200 patients
Douglas G Adler1, V. Raman Muthusamy2, Dean S Ehrlich2, Gulshan Parasher3, Nirav C Thosani4, Ann Chen5, Jonathan M Buscaglia6, Anoop Appannagari6, Eduardo Quintero6, Harry Aslanian7, Linda Jo Taylor1, Ali Siddiqui8
1 Department of Gastroenterology and Hepatology, University of Utah School of Medicine, Salt Lake City, Utah, USA
2 Department of Gastroenterology and Hepatology, University of California, Los Angeles, California, USA
3 Department of Gastroenterology and Hepatology, University of New Mexico, Albuquerque, New Mexico, USA
4 Department of Gastroenterology and Hepatology, Memorial Hermann Hospital, Houston, Texas, USA
5 Department of Gastroenterology and Hepatology, Stanford Health Care, Stanford, California, USA
6 Department of Gastroenterology and Hepatology, Stony Brook School of Medicine, Stony Brook, New York, USA
7 Department of Gastroenterology and Hepatology, Yale School of Medicine, New Haven, Connecticut, USA
8 Department of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Dr. Douglas G Adler
Department of Gastroenterology and Hepatology, University of Utah School of Medicine, Huntsman Cancer Center, 30N 1900E 4R118, Salt Lake City, Utah 84132
Source of Support: None, Conflict of Interest: None
Background and Objectives: We present a multicenter study of a new endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) needle (Acquire, Boston Scientific, Natick, MA). The aim of the study was to analyze the needle's clinical performance when sampling solid lesions and to assess the safety of this device.
Methods: We performed a multicenter retrospective study of patients undergoing EUS-FNB during July 1–November 15, 2016.
Results: Two hundred patients (121 males and 79 females) underwent EUS-FNB of solid lesions with the Acquire needle. Lesions included solid pancreatic masses (n = 109), adenopathy (n = 45), submucosal lesions (n = 34), cholangiocarcinoma (n = 8), liver lesions (n = 6), and other (n = 8). Mean lesion size was 30.6 mm (range: 3–100 mm). The mean number of passes per target lesion was 3 (range: 1–7). Rapid onsite cytologic evaluation (ROSE) by a cytologist was performed in all cases. Tissue obtained by EUS-FNB was adequate for evaluation and diagnosis by ROSE in 197/200 cases (98.5%). Data regarding the presence or absence of a core of tissue obtained after EUS-FNB were available in 145/200 procedures. In 131/145 (90%) of cases, a core of tissue was obtained. Thirteen out of 200 patients (6.5%) underwent some form of repeat EUS-based tissue acquisition after EUS-FNB with the Acquire needle. There were no adverse events.
Conclusion: Overall, this study showed a high rate of tissue adequacy and production of a tissue core with this device with no adverse events seen in 200 patients. Comparative studies of different FNB needles are warranted in the future to help identify which needle type and size is ideal in different clinical settings.